The head of the Indonesian Food and Drug Authority (BPOM), Prof. Dr. Taruna Ikrar, has issued a strong call to action for a deeply integrated collaboration between higher education institutions, private industry, and the government to secure the nation’s independence in pharmaceutical raw materials. Speaking at a prominent academic and industrial forum, the BPOM leader emphasized that systemic reliance on foreign imports poses a persistent structural vulnerability to Indonesia’s healthcare security, a challenge that can only be met through coordinated research, aggressive industrialization, and targeted downstream processing.
The imperative to reform the nation’s domestic supply chain took center stage during the Science, Technology, and Industrial Convention (KSTI) 2026, hosted at the Institut Teknologi Sepuluh Nopember (ITS) in Surabaya. Addressing a gathered audience of scientists, policymakers, and corporate leaders, Prof. Taruna presented a strategic roadmap titled National Independence in Pharmaceutical Raw Materials, laying bare the economic and clinical risks of maintaining the status quo.
The Urgency of Pharmaceutical Independence in Indonesia
For decades, the domestic pharmaceutical sector has functioned primarily as a formulation and packaging hub rather than an original synthesis producer. Industry analysts estimate that Indonesia imports roughly 90 percent of its active pharmaceutical ingredients (APIs)—the biologically active components necessary to manufacture conventional and specialized medicines. The primary source markets for these crucial raw materials include industrial powerhouses such as China and India.
This heavy reliance on foreign supply chains leaves the Indonesian domestic market acutely vulnerable to external economic shocks, geopolitical tensions, currency fluctuations, and global supply chain disruptions, such as those witnessed during the COVID-19 pandemic. When global logistics ground to a halt or supplier nations prioritize domestic consumption, Indonesia’s national health system faces immediate risks of drug shortages, escalating treatment costs, and compromised public health security.
Prof. Taruna underscored that overcoming this vulnerability requires more than incremental changes; it demands a wholesale transformation of how scientific research is funded, validated, and commercialized within the archipelago. By championing a robust framework of domestic sourcing, the nation can safeguard its healthcare sovereignty while stimulating high-value economic sectors.
The Triple Helix Model: Academia, Business, and Government
At the core of the BPOM chief’s proposal is the reinforcement of the "Triple Helix" model—a collaborative ecosystem uniting Academia, Business, and Government. According to this framework, each sector plays a distinct yet interdependent role in driving the industrialization of local scientific discoveries.
Universities are designated as the primary engines of innovation. Within this model, academic institutions must pivot their research agendas away from purely theoretical pursuits and toward applied sciences that address tangible national needs. This involves identifying viable local flora, chemical compounds, and biological agents that can be synthesized into safe and effective APIs.
Private industry acts as the critical catalyst for investment, scaling, and commercialization. Without corporate backing, groundbreaking academic discoveries risk languishing in university libraries as unpublished papers or unexploited patents. Industrial partners provide the capital, manufacturing infrastructure, and market distribution networks necessary to transform laboratory prototypes into mass-produced commercial goods that meet international quality standards.
The government, meanwhile, serves as the architect of enabling policies and regulatory frameworks. This encompasses streamlining the drug approval process, offering tax incentives for research and development (R&D), protecting intellectual property rights, and utilizing state procurement power—such as through the national health insurance scheme (BPJS Kesehatan)—to guarantee a stable market for domestically manufactured APIs.
"There is a necessary collaboration among academia, business, and government, with universities acting as the center of innovation, industry acting as the driver of investment and commercialization, and the government acting as the provider of supportive policies and regulations," Prof. Taruna stated, highlighting that this synergy prevents scientific research from terminating as mere academic publications.
Background and Highlights of KSTI 2026
The Science, Technology, and Industrial Convention (KSTI) 2026, which ran from November 10 to November 13 at the ITS campus in Surabaya, served as the premier national forum for discussing the convergence of cutting-edge science and industrial policy. The four-day event drew thousands of participants, ranging from government officials and corporate executives to prominent academics and international scientists.
A major highlight of KSTI 2026 was the inclusion of Nobel Laureate in Chemistry 2021, Prof. Benjamin List, who participated in panel discussions and knowledge-sharing sessions. The presence of a Nobel laureate underscored the convention’s global outlook, bridging international scientific breakthroughs with localized Indonesian applications, particularly in sustainable catalysis and molecular chemistry—fields critical to the efficient synthesis of pharmaceutical ingredients.
Throughout the convention, stakeholders engaged in intensive workshops, plenary sessions, and exhibitions showcasing homegrown technological innovations. Discussions consistently returned to the necessity of bridging the gap between campus laboratories and manufacturing plants, a longstanding bottleneck in Indonesia’s innovation ecosystem.
Chronology of Regulatory and Industrial Shifts
The push for domestic pharmaceutical independence is not a sudden policy shift, but rather the culmination of years of strategic planning and mounting economic pressure.
In the wake of global supply chain disruptions experienced between 2020 and 2022, the Indonesian government elevated the development of the domestic medical device and pharmaceutical raw material sectors to a national strategic priority. Subsequent legislative and executive measures have sought to incentivize local manufacturing.
- 2020–2021: The COVID-19 pandemic exposes severe vulnerabilities in Indonesia’s import-dependent medical supply chain, prompting inter-ministerial task forces to map out domestic API production capabilities.
- 2022–2023: The Ministry of Health and BPOM introduce accelerated regulatory pathways for locally developed drugs and raw materials, aiming to reduce bureaucratic hurdles for domestic innovators.
- 2024–2025: Strategic investments are funneled into state-owned pharmaceutical enterprises and private joint ventures to construct specialized API production facilities, particularly for essential antibiotics and chronic disease medications.
- November 10–13, 2026: KSTI 2026 convenes in Surabaya, where BPOM Chief Prof. Taruna Ikrar formalizes the call for a renewed, synchronized Triple Helix approach to cement these gains.
Analytical Implications for the Broader Economy
The transition toward national pharmaceutical independence carries profound implications for Indonesia’s macroeconomic landscape, healthcare equity, and technological competitiveness.
From an economic perspective, reducing API imports can substantially alleviate pressure on the national current account deficit. Billions of rupiah that historically flowed out of the country to foreign chemical suppliers can instead be retained within the domestic economy, stimulating high-tech job creation for biochemists, chemical engineers, and clinical researchers.
Clinically, a localized supply chain insulates patients from sudden price spikes caused by global inflation or foreign exchange volatility. Ensuring a steady, predictable supply of essential medicines directly supports the long-term sustainability of Universal Health Coverage (UHC), preventing drug rationing and ensuring equitable healthcare access across the sprawling archipelago.
However, industry experts caution that achieving these goals will require sustained political will and long-term capital allocation. Transitioning from import-reliance to export-readiness requires stringent adherence to international regulatory standards, such as those set by the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). BPOM’s active role in maintaining rigorous oversight while simultaneously fostering innovation will be decisive in ensuring that local products are not only self-sufficient, but globally competitive.
As KSTI 2026 concluded, the consensus among academic, industrial, and governmental delegates was clear: Indonesia possesses the scientific talent and natural resources necessary to become a regional pharmaceutical leader. Realizing this potential, however, will depend on the steadfast execution of the Triple Helix framework advocated by BPOM, transforming collaborative rhetoric into tangible, life-saving industrial reality.
